Chicago IL 星形细胞瘤临床试验
9项针对 星形细胞瘤的研究正在 Chicago及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
招募中1/2 期
- Northwestern Memorial Hospital, Chicago
Targeted Pediatric High-Grade Glioma Therapy
招募中观察性研究
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
招募中3 期
- University of Illinois, Chicago
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- University of Chicago, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Chicago
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
招募中早期 I 期欢迎健康志愿者
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
其他城市的 星形细胞瘤试验
- Houston, TX14 项研究
- Boston, MA13 项研究
- New York City, NY9 项研究
- Miami, FL7 项研究
- Seattle, WA7 项研究
- Philadelphia, PA7 项研究
- Washington, DC6 项研究
- Durham, NC6 项研究
- Columbus, OH6 项研究
- San Francisco, CA5 项研究
- Cincinnati, OH5 项研究
- Aurora, CO5 项研究
Chicago的其他研究
- 非小细胞肺癌61 项研究
- 乳腺癌58 项研究
- 癌症(所有类型)52 项研究
- 转移性癌症45 项研究
- 前列腺癌45 项研究
- 肥胖症42 项研究
- 肺癌41 项研究
- 卵巢癌36 项研究
- 卒中34 项研究
- 心力衰竭32 项研究
- 结直肠癌32 项研究
- 超重28 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月1日。每项研究自行设定入选标准,由研究团队决定谁能参与。